Wei Sun

Dr. Wei Sun


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Oncogene
Verified
Journal Article
Closed access
PDF file
SLShasha Li
Shasha Li
JLJiaming Lin
Jiaming Lin
LHLiu Huang
Liu Huang
SHShaojie Hu
Shaojie Hu
MWMingwei Wang
Mingwei Wang
SSShuguo Sun
Shuguo Sun

18 November 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SHShaojie Hu
Shaojie Hu
CYChenxi Yan
Chenxi Yan
YTYitao Tian
Yitao Tian
WSWei Sun
Wei Sun
Neutrophils, which represent about 50–70% of circulating leukocytes in humans, have been viewed as short-lived effector cells of the innate immune system with a primary role in the clearance of pathogens and taking part in inflammatory processes. More recent evidence shows that neutrophils make up a significant portion of the inflammatory cell infiltration in many types of cancer, including non-small cell lung cancer (NSCLC). These tumor-associated neutrophils (TANs) can be divided into protumorigenic and antitumorigenic phenotypes. The biological features and functions of these TANs are under the influence of the tumor microenvironment. TANs also play a role in determining the responsiveness of NSCLC to immunotherapies targeting the programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) axis. This review aimed to summarize recent findings regarding the role of TANs in NSCLC progression and PD-1/PD-L1 targeted immunotherapy.

5 November 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
XWXinghao Wang
Xinghao Wang
YWYajun Wang
Yajun Wang
MXMin Xie
Min Xie
SMShichao Ma
Shichao Ma
YZYilin Zhang
Yilin Zhang
WSWei Sun
Wei Sun
Polycomb repressive complex 2 (PRC2) catalyzes the writing of the tri-methylated histone H3 at Lys27 (H3K27me3) epigenetic marker and suppresses the expression of genes, including tumor suppressors. The function of the complex can be partially antagonized by the SWI/SNF chromatin-remodeling complex. Previous studies have suggested that PRC2 is important for the proliferation of tumors with SWI/SNF loss-of-function mutations. In the present study, we have developed an EED-directed allosteric inhibitor of PRC2 termed BR0063, which exhibits anti-proliferative properties in a subset of solid tumor cell lines harboring mutations of the SWI/SNF subunits, SMARCA4 or ARID1A. Tumor cells sensitive to BR0063 exhibited several distinct phenotypes, including cell senescence, which was mediated by the up-regulation of CDKN2A/p16. Further experiments revealed that the expression of p16 was suppressed in the BR0063-resistant cells via DNA hypermethylation in the CpG island (CGI) promoter region, rather than via PRC2 occupancy. The expression of TET1, which is required for DNA demethylation, was found to be inversely correlated with p16 CGI methylation, and this may serve as a biomarker for the prediction of resistance to PRC2 inhibitors in SWI/SNF LOF tumors.

26 August 2025 in Cellular Oncology
Verified
Journal Article
Open access
PDF file
CYChenxi Yan
Chenxi Yan
YCYanjie Chen
Yanjie Chen
YTYitao Tian
Yitao Tian
SHShaojie Hu
Shaojie Hu
HWHeng Wang
Heng Wang
WSWei Sun
Wei Sun
Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment efficacy and frequent resistance to conventional therapies. Recent advances have uncovered the critical influence of the human microbiota—complex communities of bacteria, viruses, fungi, and other microorganisms—on lung cancer pathogenesis and therapeutic responses. This review synthesizes current knowledge on the compositional and functional roles of microbiota across multiple body sites, including the gut, lung, tumor microenvironment, circulation, and oral cavity, highlighting their contributions to tumor initiation, progression, metastasis, and immune regulation. We emphasize the bidirectional communication between microbial metabolites and host immune pathways, particularly the gut–lung axis, which modulates systemic and local antitumor immunity. Importantly, microbiota composition has been linked to differential responses and toxicities in chemotherapy, radiotherapy, targeted therapy, and immune checkpoint blockade. Microbiota-targeted interventions, such as probiotics, fecal microbiota transplantation, and selective antibiotics, show promising potential to enhance treatment efficacy and mitigate adverse effects. However, challenges remain in clinical translation due to interindividual microbiome variability, mechanistic complexities, and limited longitudinal data. Future research integrating multi-omics, microbial functional profiling, and controlled clinical trials is essential to harness the microbiome as a precision medicine tool in lung cancer management. This review provides a comprehensive overview of the emerging role of microbiota in lung cancer development and therapy, offering new perspectives for innovative therapeutic strategies.

19 June 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
XZXiao Zhang
Xiao Zhang
LHLiu Huang
Liu Huang
JLJiayao Li
Jiayao Li
YCYixin Cai
Yixin Cai
WCWei Chen
Wei Chen
QCQian Chu
Qian Chu
Background: As a key downstream effector of the Hippo signaling pathway, Yes-associated protein (YAP) has emerged as a pivotal regulator of tumor immune evasion and resistance to immune checkpoint inhibitors (ICIs). However, the relationship between YAP expression and immunotherapy outcomes in patients with non-small cell lung cancer (NSCLC), as well as its potential value as a therapeutic target, remains to be systematically investigated. Methods: We retrospectively analyzed 141 patients with NSCLC who received immunotherapy, including 9 monoimmunotherapy and 132 immunotherapy plus chemotherapy or anti-angiogenic therapy. The expression of YAP in tumor tissues was evaluated by immunohistochemistry, and the association between YAP expression and immunotherapy resistance was assessed. Gene expression profiling following YAPand transcriptional coactivator with PDZ-binding motif (TAZ) knockdown was performed to identify potential YAP inhibitors and explore their underlying mechanisms of action. Furthermore, the therapeutic potential of a YAP inhibitor in reversing ICI resistance was evaluated in two patients with high YAP expression who had developed acquired resistance to immunotherapy. Results: In our cohort, which predominantly received combination immunotherapy (93.62%), high YAP expression was associated with poor clinical outcomes to immunotherapy. Notably, YAP expression outperformed Programmed Cell Death Ligand 1 (PD-L1) as a predictive biomarker for treatment response. Through screening for potential YAP inhibitors, tucidinostat (TD) was identified as a compound capable of suppressing YAP activity. In two elderly patients with advanced NSCLC who had developed acquired resistance to immunotherapy, the combination of TD with ICIs successfully restored antitumor responsiveness. Mechanistic investigations further revealed that TD suppressed YAP expression via SNAI2-mediated epigenetic regulation, thereby blocking YAP-dependent tumor proliferation and immune evasion. Conclusions: YAP is a strong predictive biomarker of response to immunotherapy in NSCLC. The combination of TD and ICIs shows promise in reversing immunotherapy resistance associated with high YAP expression, offering a potential strategy to overcome acquired resistance.

1 August 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
CYChenxi Yan
Chenxi Yan
SHShaojie Hu
Shaojie Hu
YTYitao Tian
Yitao Tian
XZXiaoxue Zhang
Xiaoxue Zhang
WSWei Sun
Wei Sun
Background: Distinguishing multiple primary lung adenocarcinomas (MPLAs) from intrapulmonary metastases (IPMs) is essential for accurate staging and treatment planning. However, existing histologic and molecular criteria remain limited in diagnostic accuracy. Spread through air spaces (STAS) has been recognized as a marker of tumor aggressiveness, but its role in differentiating MPLA from IPM remains unclear. This study aimed to assess whether STAS can serve as a supportive marker to differentiate IPM from MPLA under both histologic and molecular frameworks. Methods: We retrospectively enrolled 170 patients who were preoperatively diagnosed with MPLA and underwent surgical resection of multiple lung lesions. Clinical, histopathologic, and molecular data—including broad-panel next-generation sequencing (NGS) results [e.g., epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), tumor protein p53 (TP53), among others]—were collected. Tumors were classified as MPLA or IPM using histologic criteria alone and a combined histologic-molecular algorithm. The presence and quantity of STAS were evaluated and analyzed as potential predictors of IPM. Results: STAS was more frequent in the IPM group across both classification methods and was an independent predictor of IPM. Driver gene mutations (e.g., EGFR, KRAS) differed significantly between MPLA and IPM. The 83.5% concordance between histologic and combined classifications suggests potential bias in histology alone. In resource-limited settings, STAS may offer a cost-effective adjunct to support IPM diagnosis when molecular data are unavailable. Conclusions: STAS is associated with IPM and may serve as a supportive diagnostic marker when distinguishing IPM from MPLA. In resource-limited settings where molecular testing is not always available, STAS may offer a practical, cost-effective histologic adjunct to guide clinical decision-making.